BNET Industries

BNET Pharma

Industry news and insights by Jim Edwards

Pharma Roundup: Obama May Decrease Drug Revenue, Strong Viagra and Cialis Sales, and More

By John Maas | October 23rd, 2008 @ 5:16 pm

Obama health plan could cost pharma billions — According to Boston Consulting Group, the Obama health plan’s provision for negotiations on Medicare drug prices could cost drug makers between $10 and $30 billion in revenue. Obama has still received three times the donations McCain has received from drug companies, perhaps because McCain campaigned for similarly expensive negotiations as a senator. [Source: WSJ Health Blog]

Viagra and Cialis sales still swelling — Despite the economy, Q3 sales of Pfizer’s Viagra climbed over the same period last year. Sales of Lilly’s Cialis rose compared to last quarter. Both companies attributed the gain to price hikes, but still…. [Source: Pharma's Market]

Glaxo opts for transparency — Joining a number of similar announcements from a few weeks ago, Glaxo has said it will publicize its payments to doctors and other academics, and will (still somewhat generously) cap those payments at $150,000 per year. [Source: Pharmalot]

Contract manufacturing worth $20 billion — The worldwide pharmaceutical contract manufacturing industry–outsourcing–is worth $20.4 billion this year, the firm Global Industry Analysts estimates. Predicted worth in 2012 is $31 billion. [Source: Pharma Times]

Tags: Revenue, Pharmaceutical Company, Health Care, Viagra, Vertical Industries, Benefits, Healthcare, Manufacturing, Enterprise Software, Software

 

BNET TalkbackShare your ideas and expertise on this topic

The following tags are supported in BNET comments:
<b></b> <i></i> <u></u> <pre></pre>

Leave a Reply

  1. You are currently a guest | Login?
  2.  
advertisement
Go
advertisement
  • Click Here
  • Click Here
advertisement
AboutPharma Industry

BNET Pharma provides daily industry news coverage and insights for managers and executives about the major manufacturers of pharmaceuticals and medicine. In addition to detailed company profiles, we bring you critical analysis on new alliances and partnerships, new patents and products, mergers and acquisitions, cost management, investments and deal flow, and a host of other important business issues.